CCT2 and breast carcinoma: The addition of an anti-CCT2 antibody to the CSS platform resulted in improved CTC image analysis and increased detection of rare breast cancer and SCLC cells spiked into blood, which was confirmed in a pilot study of blood from SCLC patients.